ACTU - Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc. Common stock Logo

ACTU - Actuate Therapeutics, Inc. Common stock

https://actuatetherapeutics.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
This Actuate Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday - CareDx ( NASDAQ:CDNA ) , Actuate Therapeutics ( NASDAQ:ACTU )
Benzinga • 2 weeks, 6 days ago • score: 0.46
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B. Riley Securities analyst Mayank Mamtani initiated coverage on Actuate Therapeutics, Inc.
AI Tools
Key Metrics
Trend: Downtrend
As of 2025-09-10 (Snapshot)

None

52W High
$11.99
52W Low
$5.47
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
N/A
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
1977.80
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
17.81%
Institutions (25–75% balanced)
54.01%
Shares Outstanding
20,745,200
Float
10,398,700
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-3.11
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
N/A
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
-0.1625
Previous
-0.0371
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025